홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

Levofloxacin Hydrate

HCID 3033924
새 노트새 반응견적 요청하기
인쇄 미리보기
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
138199-71-0
표준 SMILES
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.O
InChIKey
SUIQUYDRLGGZOL-RCWTXCDDSA-N
분자식
C36H42F2N6O9
평균 분자량
740.7 g/mol
단동위원소 질량
740.29813326

개요

Levofloxacin is a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. Levofloxacin is marketed by Ortho-McNeil under the trade name Levaquin. Chemically, levofloxacin is the S-enantiomer (L-isomer) of ofloxacin.

이름 및 식별자

우선 이름
Levofloxacin Hydrate
IUPAC
bis((2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid);hydrate
영어명
Levofloxacin heMihydrate
분자식
C18H22FN3O5
분자량
379.39

이름 및 동의어

Levofloxacin hydrateDTXSID60160533RefChem:1088440DTXCID2083024(3S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acid hemihydrate138199-71-0DynaquinMFCD07772024Levofloxacin (hydrate)(S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate(2:1)7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (3S)-(S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hemihydrate
이름 더 보기
LevofloxacineLEVOFLOXACIN HCL(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)3-de)-1Iquix hydrate(S)-9-Fluoro-2Cravit hydrateQuixin hydrate
7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-hydrate (2:1), (S)-Levofloxacin [USAN]RWJ 25213Quixin (TN)Iquix (TN)(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;hydrateUNII-6GNT3Y5LMFLevofloxacin hemihydrate CRS

데이터베이스 식별자

CAS
138199-71-0
PubChem CID
3033924
DTXSID
DTXSID60160533
ChEMBL
CHEMBL5315124
UNII
6GNT3Y5LMF
EC Number
604-067-2

물성

구조 계산 물성

극성 표면적
148 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
17
회전 가능 결합 수
4
무거운 원자 수
53
형식 전하
0
복잡도
634

실험 및 물리화학적 성질

Dissociation Constants · 4건

8.12

6.1

6

8.6

물리화학적 성질

녹는점
214 · 214-216°C
저장 조건
2 · Sealed in dry,2-8°C
용해도
수용성 염기(약간 용해됨), DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
Solid
색상
연한 노란색에서 밝은 노란색까지
주요 응용
의약품(소분자)
InChI
1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1
InChIKey
SUIQUYDRLGGZOL-RCWTXCDDSA-N
SMILES
O.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O.C[C@H]5COc6c(N7CCN(C)CC7)c(F)cc8C(=O)C(=CN5c68)C(O)=O

화학적 성질

Pale Yellow Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H302 (99.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P233, P260, P261, P263, P264, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P318, P321, P330, P333+P317, P342+P316, P362+P364, P403, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 114 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (99.1%)

독성 정보

TreatmentIn the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis. (L1009)
Health Effects · 1건

Irreversible peripheral neuropathy, central nervous system toxicity, cardiovascular toxicity, tendon / articular toxicity, and hepatic toxicity. Toxic epidermal necrolysis, coagulation abnormalities and pancytopenia are other possible adverse effect of levofloxacin. Administration of commercial levofloxin (Levaquin), increased risk of tendinitis and tendon rupture in all ages. This adverse reaction most frequently involves the Achilles tendon (L1009, L1017).

Exposure RoutesIngestion; injection; skin contact (L1017). Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
Toxicity Summary · 1건

Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.

Signs and SymptomsSide effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD50: 640 mg/kg (Oral, Rat)

안전 데이터

wgk
3
HS 번호
2934990002
risk_code
50/53
hazard_code
N
safety_code
24/25-61-60
Hazard Classifications
Acute Tox. 4 OralResp. Sens. 1Skin Sens. 1
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans. Levofloxacin is rapidly and essentially completely absorbed after oral administration. It is distributed into body tissues, especially in the skin and lung tissues. Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity. Levofloxacin is excreted largely as unchanged drug in the urine (L1009). Route of Elimination: Mainly excreted as unchanged drug in the urine. Half Life: 6-8 hours

용도 및 제조

Uses · 1건

For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: <i>Corynebacterium</i> species, <i>Staphylococus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Streptococcus pneumoniae</i>, <i>Streptococcus</i> (Groups C/F/G), Viridans group streptococci, <i>Acinetobacter lwoffii</i>, <i>Haemophilus influenzae</i>, <i>Serratia marcescens</i>. Levofloxacin is a synthetic chemotherapeutic agent used to treat severe and life threatening bacterial infection (L1009).

응용 분야

용도Levofloxacin heMihydrate is an antibiotic used against gram-negative organisms.

상·하류 제품 정보

상류 원료

만데릭산

관련 반응

12건
반응 기록 만들기
HRID 31371 반응식
HRID 31371생성물로uspto-grants-2008_09
HRID 31372 반응식
HRID 31372생성물로uspto-grants-2008_09
HRID 31373 반응식
HRID 31373생성물로uspto-grants-2008_09
HRID 31374 반응식
HRID 31374생성물로uspto-grants-2008_09
HRID 31375 반응식
HRID 31375생성물로uspto-grants-2008_09
HRID 31376 반응식
HRID 31376생성물로uspto-grants-2008_09
HRID 1866748 반응식
HRID 1866748생성물로uspto-grants-2009_12
HRID 1866749 반응식
HRID 1866749생성물로uspto-grants-2009_12
1 / 2 페이지

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기